Phillip G. Febbo's most recent trade in Veracyte Inc was a trade of 10,405 Common Stock done at an average price of $42.9 . Disclosure was reported to the exchange on Sept. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 42.89 per share. | 02 Sep 2026 | 10,405 | 135,753 (0%) | 0% | 42.9 | 446,305 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.88 per share. | 02 Sep 2026 | 3,639 | 146,158 (0%) | 0% | 44.9 | 163,318 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 43.66 per share. | 02 Sep 2026 | 2,705 | 133,048 (0%) | 0% | 43.7 | 118,105 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.80 per share. | 02 Jun 2026 | 3,730 | 149,797 (0%) | 0% | 47.8 | 178,294 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 29,603 | 146,949 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 6,578 | 153,527 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 36.16 per share. | 02 Mar 2026 | 13,425 | 117,346 (0%) | 0% | 36.2 | 485,429 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.01 per share. | 02 Mar 2026 | 6,035 | 130,771 (0%) | 0% | 36.0 | 217,320 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 71,806 | 161,292 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.75 per share. | 26 Feb 2026 | 24,486 | 136,806 (0%) | 0% | 38.8 | 948,833 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.16 per share. | 02 Dec 2025 | 2,955 | 89,486 (0%) | 0% | 46.2 | 136,403 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 06 Oct 2025 | 8,349 | 92,441 (0%) | 0% | 36.0 | 300,709 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.11 per share. | 02 Sep 2025 | 2,955 | 100,790 (0%) | 0% | 30.1 | 88,975 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 2,955 | 103,745 (0%) | 0% | 26.7 | 79,017 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 24,160 | 106,700 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 04 Mar 2025 | 4,467 | 86,110 (0%) | 0% | 32.9 | 146,808 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 33.95 per share. | 04 Mar 2025 | 3,570 | 82,540 (0%) | 0% | 34.0 | 121,205 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 30,589 | 113,003 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 15,672 | 97,331 (0%) | 0% | 33.8 | 530,340 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 6,754 | 90,577 (0%) | 0% | 34.8 | 234,769 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 44.09 per share. | 04 Dec 2024 | 3,934 | 82,414 (0%) | 0% | 44.1 | 173,447 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 6,738 | 86,348 (0%) | 0% | 44.1 | 297,281 | Common Stock |
| Veracyte Inc | Dr. Phillip G. Febbo, M.D. | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 39,904 | 93,086 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,556 | 14,786 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | 01 Mar 2023 | 4,534 | 4,534 | - | - | Performance Shares | ||
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | 01 Mar 2023 | 3,023 | 3,023 | - | - | Performance Shares | ||
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,522 | 8,475 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | 21 Feb 2023 | 3,522 | 0 | - | - | Performance Shares | ||
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 202.84 per share. | 21 Feb 2023 | 1,245 | 7,230 (0%) | 0% | 202.8 | 252,536 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.19 per share. | 05 Nov 2022 | 821 | 4,953 (0%) | 0% | 217.2 | 178,313 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 360.01 per share. | 05 Apr 2022 | 1,988 | 5,774 (0%) | 0% | 360.0 | 715,700 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 360.01 per share. | 05 Apr 2022 | 1,988 | 5,774 (0%) | 0% | 360.0 | 715,700 | - |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 363.84 per share. | 05 Apr 2022 | 131 | 7,762 (0%) | 0% | 363.8 | 47,663 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 363.84 per share. | 05 Apr 2022 | 131 | 7,762 (0%) | 0% | 363.8 | 47,663 | - |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | 01 Mar 2022 | 9,085 | 9,085 | - | - | Performance Shares | ||
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 3,029 | 7,893 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | 22 Feb 2022 | 2,851 | 0 | - | - | Performance Shares | ||
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,851 | 5,866 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,851 | 5,866 (0%) | 0% | 0 | - | |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 319.86 per share. | 22 Feb 2022 | 1,002 | 4,864 (0%) | 0% | 319.9 | 320,500 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 319.86 per share. | 22 Feb 2022 | 1,002 | 4,864 (0%) | 0% | 319.9 | 320,500 | - |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 406.83 per share. | 05 Nov 2021 | 1,000 | 3,015 (0%) | 0% | 406.8 | 406,830 | Common Stock |
| Illumina Inc | Dr. Phillip G. Febbo, M.D. | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 408.14 per share. | 05 Nov 2021 | 446 | 4,015 (0%) | 0% | 408.1 | 182,030 | Common Stock |